Treatment-level association between OR for derived overall response rate and HR for overall survival for a RWD cohort from the Flatiron Health MM database.
MULTIPLE MYELOMA
Each dot in the plot represents one comparison in one cohort. For the treatment-level association analysis, only the significant ORs and HRs from the comparative analyses were used. PI+steroid was used as the comparator treatment group for all analyses. Error bars show the 95% CI of the estimated ORs and HRs. chemo, chemotherapy (cyclophosphamide, doxorubicin, melphalan, vincristine, bendamustine); CI, confidence interval; HR, hazard ratio; IMiD, immunomodulatory drug (lenalidomide, pomalidomide, thalidomide); MM, multiple myeloma; OR, odds ratio; ORR, overall response rate; OS, overall survival; PI; proteasome inhibitor (bortezomib, carfilzomib, or ixazomib); RWD, real-world data; steroid: dexamethasone, prednisone methylprednisolone, prednisolone.